Triplet Therapy for Multiple Myeloma
Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.
Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.
Clinical Pearls
Triplet therapies are often a combination of a novel drug (an IMiD or proteasome inhibitor) with two other agents or an IMiD and proteasome inhibitor with steroids. McCarthy says that triplet therapy is becoming a part of the gold standard for upfront myeloma treatment.
- The current thinking is moving away from doublet therapy and towards triplet therapy for myeloma
- Common triplet therapy regimens include:
- lenalidomide + bortezomib + dexamethasone
- cyclophosphamide + lenalidomide + dexamethasone
- cyclophosphamide + bortezomib + dexamethasone
- Triplet therapy is becoming a part of the gold standard for upfront myeloma treatment
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
